Milestone Pharmaceuticals (NASDAQ:MIST) Given “Buy” Rating at HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MISTGet Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $1.86 EPS.

Milestone Pharmaceuticals Trading Down 2.0 %

MIST opened at $1.98 on Monday. The firm’s fifty day moving average is $1.97 and its two-hundred day moving average is $1.67. The firm has a market cap of $105.59 million, a PE ratio of -2.44 and a beta of 1.78. Milestone Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $2.75. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40.

Milestone Pharmaceuticals (NASDAQ:MISTGet Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. Equities research analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MIST. Valeo Financial Advisors LLC lifted its holdings in shares of Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after purchasing an additional 10,000 shares in the last quarter. Atria Investments Inc grew its stake in shares of Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares in the last quarter. BML Capital Management LLC lifted its position in shares of Milestone Pharmaceuticals by 3.0% in the third quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after purchasing an additional 33,196 shares in the last quarter. Finally, PVG Asset Management Corp bought a new position in Milestone Pharmaceuticals in the third quarter valued at $46,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

(Get Free Report)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

Featured Stories

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.